Can the Onset of Neovascular Age-Related Macular Degeneration Be an Acceptable Endpoint for Prophylactic Clinical Trials?

Many studies over the past 20 years have pursued the goal of preventing or deferring progression from early and intermediate age-related macular degeneration (AMD) to advanced AMD. The onset of neovascular AMD has been used as a primary endpoint in some prophylactic clinical trials because it is eas...

Full description

Saved in:
Bibliographic Details
Published inOphthalmologica (Basel) Vol. 244; no. 5; pp. 379 - 386
Main Authors Mendonça, Luísa S.M., Levine, Emily S., Waheed, Nadia K.
Format Journal Article
LanguageEnglish
Published Basel, Switzerland 01.11.2021
Subjects
Review Article
Neovascular AMD
Clinical trial endpoints
Intermediate AMD
Age-related macular degeneration (AMD)
Prophylactic clinical trials
Online AccessGet full text

Cover

More Information
Summary:Many studies over the past 20 years have pursued the goal of preventing or deferring progression from early and intermediate age-related macular degeneration (AMD) to advanced AMD. The onset of neovascular AMD has been used as a primary endpoint in some prophylactic clinical trials because it is easy to assess and relatively well-defined. Nevertheless, the use of this endpoint for assessing progression of AMD lacks validation. The aims of this paper are to review the current practice of clinical trials investigating the prevention of progression of early or intermediate AMD to neovascular AMD, so-called prophylactic trials, as well as identify ongoing efforts to standardize endpoints and select the ideal population for such studies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISBN:9783318070378
3318070378
ISSN:0030-3755
1423-0267
DOI:10.1159/000513083